Eli Lilly Strikes $1.12B Gene Editing Deal With Seamless

Eli Lilly has signed a deal worth up to $1.12 billion with private gene-editing company Seamless Therapeutics, marking one of its biggest moves yet into next-generation genetic medicine.

The deal reinforces the efforts of Eli Lilly to go beyond the conventional prescription drug and in to the innovative treatments that help restore hearing loss.

Through the collaboration, Lilly will partner with Seamless to create therapies with the help of the programmable recombinase technology developed by the biotech company. This method enables the ability to make accurate changes in the DNA without the natural process of repairing the cells in the body which may enhance accuracy and minimize side effects. The firms will target the genetic hearing impairment forms, in which there is minimum treatment.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

The agreement involves a preliminary payment to Seamless, research payments, and milestone payments that are based on the development and commercial success. Although the total of the $1.12 billion will be determined by the advancements, the magnitude of the deal is an indication that they are confident in the platform. Lilly will be the global leader in clinical development and commercialization.

In the case of Eli Lilly, the collaboration is best aligned in a larger strategy of establishing a pipeline in high-impact diseases with state-of-the-art science. The firm has been running aggressive expansion in terms of buying and forming alliances as the firm seeks to offset the blockbuster diabetes and obesity drugs with long-term innovation.

Seamless, with headquarters in Germany, gets access to global development experience and scale of Lilly. Provided it is successful, the joint effort would lead to the introduction of new gene-editing therapies beyond hearing loss, with use of the same technology.

The announcement points out that the use of gene editing has gained popularity among the major drugmakers as they fight to determine the future of medicine.